According to a report published by the New York Times, Johnson & Johnson has agreed to pay approximately $2.2 billion to resolve an investigation into the marketing of one of its drugs, Risperdal.
Back in 2010, the Justice Department joined a class action accusing the company of paying out tens of thousands of dollars in illegal kickbacks to Omnicare, a company that provided nursing homes with prescription medications.
According to the class action, Johnson & Johnson gave the kickbacks in order to increase the sales of Risperdal, even though it had been linked to an increase in the risk for death in patients with dementia.
Johnson & Johnson also faced lawsuits that claim the company failed to disclose important information about the side effects of the drug.
Source:
For more information, contact the defective drug lawyers at Flood Law Group today.
